Mirikizumab (LY3074828) is a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), modulating immune response by inhibiting IL-23 binding to IL-23R, used in studies of ulcerative colitis.
Purity:
95.00%
CAS Number:
[1884201-71-1]
Target:
Interleukin|||IL Receptor
* VAT and and shipping costs not included. Errors and price changes excepted